SCHEMBL945898

SCHEMBL945898

O=C(O)C(O)CCCCCO

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 4/20 0.64
FFAR1 O14842 2/20 0.64
TET2 Q6N021 3/20 0.48
KDM4A O75164 2/20 0.48
KDM4C Q9H3R0 2/20 0.48
KDM2A Q9Y2K7 2/20 0.48
TET3 O43151 1/20 0.48
OR51E2 Q9H255 1/20 0.48
TBXAS1 P24557 2/20 0.44
FFAR4 Q5NUL3 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.40
PTPN1 P18031 1/20 0.39
KDM4E B2RXH2 1/20 0.37
CAMK2A Q9UQM7 1/20 0.36
MAPT P10636 1/20 0.35
LCK P06239 1/20 0.35
PPARD Q03181 1/20 0.35
ZDHHC20 Q5W0Z9 1/20 0.35
ZDHHC2 Q9UIJ5 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6056810 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL5703613 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL8984407 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL6056821 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL6056894 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL8984535 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL327411 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL8984493 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL7172857 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C
SCHEMBL3793029 1.00 GPR84 (0.64) GPR84FFAR1TET2KDM4AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116399-A1 Tumor Homing Statin Derivatives Da Zen Theranostics, Inc. (US) 2023-04-13 US claimed
CN-114686092-A Photocureable coating capable of being used for metal protection and preparation method thereof 中海油常州涂料化工研究院有限公司 2022-07-01 CN claimed
US-20210008217-A1 Tumor Homing Statin Derivatives Da Zen Theranostics, Inc. (US) 2021-01-14 US claimed
EP-3763389-A1 TUMOR HOMING STATIN DERIVATIVES Da Zen Theranostics Inc. (US) 2021-01-13 EP claimed
CN-111068064-A Composition comprising fatty acid or derivative thereof and dihydroxyheptanoic acid derivative 黄泳华 2020-04-28 CN claimed
CN-110590638-A Tumor-targeted statin derivative, pharmaceutical formulation and application 德珍(中国)医疗科技有限公司 2019-12-20 CN claimed
US-9296702-B2 Rosuvastatin enantiomer compounds SCALLEN, MICHAEL 2016-03-29 US claimed
US-8729092-B2 Rosuvastatin enantiomer compounds SCALLEN, MICHAEL 2014-05-20 US claimed
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY 2014-03-20 US claimed
EP-2049102-A2 POLYMORPHIC FORMS OF AN HMG-COA REDUCTASE INHIBITOR AND USES THEREOF RANBAXY LABORATORIES, LTD. (IN) 2009-04-22 EP claimed
WO-2004106299-A2 SUBSTITUTED PYRROLE DERIVATIVES AND THEIR USE AS HMG-CO INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2004-12-09 WO claimed
EP-1470106-A1 METHOD OF MANUFACTURING AN AMORPHOUS FORM OF THE HEMI-CALCIUM SALT OF (3R, 5R) 7- 3-PHENYL-4-PHENYLCARBAMOYL-2-(4-FLUOROPHENYL)-5-ISOPROPYL-PYRROL-1-YL!-3, 5-DIHYDROXYHEPTANOIC ACID (ATORVASTATIN) Zentiva, A.S. (CZ) 2004-10-27 EP claimed
WO-2004027075-A2 CHEMOENZYMATIC METHODS FOR THE SYNTHESIS OF STATINS AND STAIN INTERMEDIATES DIVERSA CORPORATION (US) 2004-04-01 WO claimed
WO-2003068739-A1 METHOD OF MANUFACTURING AN AMORPHOUS FORM OF THE HEMI-CALCIUM SALT OF (3R, 5R) 7- 3-PHENYL-4-PHENYLCARBAMOYL-2-(4-FLUOROPHENYL)-5-ISOPROPYL-PYRROL-1-YL!-3, 5-DIHYDROXYHEPTANOIC ACID (ATORVASTATIN) ZENTIVA A.S. (CZ) 2003-08-21 WO claimed
JP-2003518086-A 2003-06-03 JP claimed
EP-1242365-A1 ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALISED AUXILIARY ARM OM Pharma (CH) 2002-09-25 EP claimed
WO-2001046126-A1 ACYL PSEUDODIPEPTIDES WHICH CARRY A FUNCTIONALISED AUXILIARY ARM OM PHARMA (CH) 2001-06-28 WO claimed
EP-0494120-A1 HMG-CoA reductase inhibitors BRITISH BIO-TECHNOLOGY LIMITED (GB) 1992-07-08 EP claimed
EP-0480986-A1 6-(HYDRONAPHTYL-1-ETHYL)-4-HYDROXY-3,4,5,6-TETRAHYDRO-2H-PYRAN-2-ONES AND THE CORRESPONDING HYDROXY ACIDS BRITISH BIO-TECHNOLOGY LIMITED (GB) 1992-04-22 EP claimed
US-4775681-A Method of treating fungal infections with trans-6-[2-substitutedpyrrol-1-yl)alkyl]-4-hydroxypyran-2-ones WARNER-LAMBERT COMPANY (US) 1988-10-04 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230116399-A1 Tumor Homing Statin Derivatives HMGCR, DHCR7, DHODH GPR84 1496/4885FFAR1 953/4885TET2 3017/4885
US-20140080788-A1 NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS GRK5, GPBAR1, GPR55 GPR84 60/4885FFAR1 31/4885TET2 4168/4885
US-20210008217-A1 Tumor Homing Statin Derivatives HMGCR, DHCR7, DHODH GPR84 1496/4885FFAR1 953/4885TET2 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.